ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.

Ivana Gojo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.